$12 million grant aimed at probing how vaccines induce lasting immunity | Washington University School of Medicine in St. Louis
Study may inform design of next-generation COVID-19, flu vaccines
Related Articles
CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer
CAN-2409 plus valacyclovir and radiation therapy significantly improved DFS in intermediate- to high-risk localized prostate cancer.
Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL
Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.
CPX-351 vs 7+3: AML-MR Mutations Drive the Benefit of CPX-351 Over 7+3
With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in treating acute myeloid leukemia with mutations in measurable…
Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies
Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.
Immune-Related Adverse Events Webinar Series #12
Join us for a virtual session where learners will hear from experts in the field in a didactic & panel case discussion format.
Uproleselan Plus Chemo Fails to Produce OS Benefit in Relapsed/Refractory AML
The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial
PURPOSETo assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC).METHODSIn this trial, patients…
Our Most Loved Pieces of 2024 – Boston Review
The essays, reviews, forums, and interviews that readers turned to the most.
Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor-Naive Myelofibrosis
Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.